Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Lexicon Pharmaceuticals announced presentations of clinical study data for sotagliflozin in Type 1 diabetes and pilavapadin in diabetic peripheral neuropathic pain at the 2026 ADA Scientific Sessions. Sotagliflozin, an oral SGLT1/2 inhibitor, shows continued potential ahead of a planned NDA resubmission in mid-2026. Pilavapadin, targeting neuropath…